Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Hepatoblastoma 1

Interventions

X-Rays 4Phantoms, Imaging 4Cyclophosphamide 4fludarabine 3Specimen Handling 3Melphalan 3Magnetic Resonance Spectroscopy 3ulixertinib 2tipifarnib 2tazemetostat 2talazoparib 2selpercatinib 2palbociclib 2ivosidenib 2Vemurafenib 2Temozolomide 2Sirolimus 2Nuclear Medicine Department, Hospital 2Nivolumab 2LY3023414 2Granulocyte Colony-Stimulating Factor 2Busulfan 2regorafenib 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1olaparib 1larotrectinib 1irinotecan sucrosofate 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Ewing × Honey × Gastrointestinal × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡